Elderly patient

UCLH start clinical trial for Alzheimer’s drug treatment

The University College London Hospitals NHS FT (UCLH) has developed a clinical trial for a new drug candidate for Alzheimer’s disease, with participants now being screened.

Those participating in the trial will already have the rare inherited form of Alzheimer’s disease. The aim of the drug – known as E2814 – is to target tau protein found in the brain, which is recognised as being responsible for the progression of the disease.

This is the first time a treatment targeting tau is being trialled in patients with the inherited form of Alzheimer’s disease. It is common for those inheriting the mutations that cause Alzheimer’s disease, to develop the cognitive impairments of the disease at an earlier and more predictable age. They often develop symptoms around the same age as their parents; in their 50s, 40s and even 30s.

The program will evaluate three anti-tau drugs in clinical studies, determining whether these drugs can slow or stop the progress of Alzheimer’s disease.

The trial is being carried out by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), which is an international collaboration sponsored by the Washington University School of Medicine, to test new experimental therapies for Alzheimer’s.

DIAN-TU’S UK Chief Investigator Dr Cath Mummery; consultant neurologist at the National Hospital for Neurology and Neurosurgery; and head of clinical trials at the Dementia Research Centre at UCL, said: “As we’ve learned more about Alzheimer’s, we understand that tau plays a critical role in disease progression alongside amyloid; this is the first anti-tau treatment we will study in these families with genetic forms of Alzheimer’s disease and this important work advances the field towards our goal of discovering an effective treatment for this devastating disease."

The E2814 drug was developed by Professor Rohan De Silva at the Reta Lila Weston Institute, and UCL Queen Square Institute of Neurology, as part of the Therapeutic Innovation Group.

If the treatment is shown to work, it will benefit patients with the more common, sporadic forms of Alzheimer’s disease in the older population by, at least, slowing further progression of the disease.

NHE May/June 22

NHE May/June 22

Developing a high-quality NHS estate

The new edition of NHE’s e-magazine highlights the latest in cyber security, pharmaceuticals, NHS workforce, NHS Estates, driving innovation in procurement and more with articles from the likes of Brendan Griffin-Ryan, Senior Category Manager, Estates & Facilities, NHS SBS (pg79), West London NHS Trust and Health Education England.

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all